Glucagon and GLP-1 receptor co-agonist
Survodutide 6.0 mg subcutaneous once weekly
SURV_SC_6p0MG_QW
Related
- All doses pooled: Survodutide injection
- Survodutide 0.3 mg subcutaneous once weekly
- Survodutide 0.9 mg subcutaneous once weekly
- Survodutide 1.8 mg subcutaneous once weekly
- Survodutide 2.7 mg subcutaneous once weekly
- Survodutide 1.2 mg injection
- Survodutide 1.8 mg injection
- Survodutide 0.6 mg subcutaneous once weekly
- Survodutide 2.4 mg subcutaneous once weekly
- Survodutide 3.6 mg subcutaneous once weekly
- Survodutide 4.8 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Serious adverse events | longest follow-up | Placebo | HR 0.87 (0.26 to 2.85) | 0.65 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.53 (0.88 to 7.53) | 0.32 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Nausea | longest follow-up | Placebo | HR 5.31 (1.81 to 14.84) | 0.21 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Vomiting | longest follow-up | Placebo | HR 6.96 (1.62 to 27.28) | 0.36 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Diarrhea | longest follow-up | Placebo | HR 3.36 (1.05 to 10.42) | 0.17 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Constipation | longest follow-up | Placebo | HR 3.14 (0.86 to 10.56) | 0.27 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.81 (1.39 to 21.37) | 0.26 |